Key result
Add-on empagliflozin shows no benefit over placebo for arterial stiffness in T2D and CVD.
Why the study?
Although SGLT2 inhibition has preventive and therapeutic effects on heart failure, its clinical effect on arterial stiffness remains controversial.
Does add-on empagliflozin improve arterial stiffness in patients with type 2 diabetes and cardiovascular disease?
RCT (n=26)
Double-blind
Web-based minimization dynamic allocation method
Yes
Does add-on empagliflozin improve arterial stiffness in patients with type 2 diabetes and cardiovascular disease?
Mean Difference: 11.2 (95% CI -108.1–130.5)
Absolute Event Rate: 54.9% vs 43.7%
p-value: p=0.848
Add-on empagliflozin did not reduce baPWV; leaves open whether longer treatment or other vascular measures confer benefit in T2D with CVD.
Background: Although sodium glucose co-transporter 2 (SGLT2) inhibition has been proven to have preventive and therapeutic effects on heart failure, its clinical effect on arterial stiffness remains controversial. Herein, we sought to assess the effect of add-on empagliflozin treatment on arterial stiffness, assessed as brachial-ankle pulse wave velocity (baPWV), in patients with type 2 diabetes (T2D) and cardiovascular disease (CVD).
No takes yet. Share an insight, caveat, or question.
Tanaka et al. (2022) conducted an RCT in Type 2 diabetes and cardiovascular disease (n=26). Empagliflozin vs. Placebo was evaluated on Change in brachial-ankle pulse wave velocity (baPWV) from baseline to week 24 (MD 11.2 cm/s, 95% CI -108.1 to 130.5, p=0.848). Add-on empagliflozin treatment for 24 weeks did not significantly affect arterial stiffness compared to placebo in patients with type 2 diabetes and cardiovascular disease (mean difference 11.2 cm/s, P = 0.848).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: